

Audit Review Table				
Presbyterian Health Plan, Inc. (Org ID: 579, SubID: 4104, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2019; Date & Timestamp - 6/11/2020 6:10:43 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and Screening				
Adult BMI Assessment (aba)		85.40%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)				
BMI Percentile		61.56%	R	Reportable
Counseling for Nutrition		50.85%	R	Reportable
Counseling for Physical Activity		49.15%	R	Reportable
Childhood Immunization Status (cis)				
DTaP		74.94%	R	Reportable
IPV		89.05%	R	Reportable
MMR		87.35%	R	Reportable
HIB		86.62%	R	Reportable
Hepatitis B		91.00%	R	Reportable
VZV		87.35%	R	Reportable
Pneumococcal Conjugate		78.83%	R	Reportable
Hepatitis A		87.59%	R	Reportable
Rotavirus		76.89%	R	Reportable
Influenza		51.09%	R	Reportable
Combination #2		72.75%	R	Reportable
Combination #3		69.83%	R	Reportable
Combination #4		69.59%	R	Reportable
Combination #5		64.23%	R	Reportable
Combination #6		43.55%	R	Reportable
Combination #7		63.99%	R	Reportable
Combination #8		43.31%	R	Reportable
Combination #9		40.39%	R	Reportable
Combination #10		40.15%	R	Reportable
Immunizations for Adolescents (ima)				
Meningococcal		77.86%	R	Reportable
Tdap		85.40%	R	Reportable
HPV		35.52%	R	Reportable
Combination #1		76.16%	R	Reportable
Combination #2		32.85%	R	Reportable
Lead Screening in Children (lsc)		37.23%	R	Reportable
Breast Cancer Screening (bcs)		49.55%	R	Reportable
Cervical Cancer Screening (ccs)		45.26%	R	Reportable
Chlamydia Screening in Women (chl)				
16-20 Years		47.61%	R	Reportable
21-24 Years		58.71%	R	Reportable
Total		52.37%	R	Reportable
Effectiveness of Care: Respiratory Conditions				
Appropriate Testing for Pharyngitis (cwp)	Y			
3-17 Years		80.05%	R	Reportable
18-64 Years		74.09%	R	Reportable
65+ Years		84.62%	NA	Small Denominator
Total		78.05%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)		22.75%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y			
Systemic Corticosteroid		52.19%	R	Reportable
Bronchodilator		58.36%	R	Reportable
Medication Management for People With Asthma (mma)	Y			
5-11 Years: Medication Compliance 50%		60.30%	R	Reportable
5-11 Years: Medication Compliance 75%		33.73%	R	Reportable
12-18 Years: Medication Compliance 50%		60.42%	R	Reportable
12-18 Years: Medication Compliance 75%		34.97%	R	Reportable
19-50 Years: Medication Compliance 50%		70.66%	R	Reportable
19-50 Years: Medication Compliance 75%		44.19%	R	Reportable
51-64 Years: Medication Compliance 50%		80.75%	R	Reportable
51-64 Years: Medication Compliance 75%		59.25%	R	Reportable
Total: Medication Compliance 50%		65.93%	R	Reportable
Total: Medication Compliance 75%		40.27%	R	Reportable
Asthma Medication Ratio (amr)	Y			
5-11 Years		69.89%	R	Reportable

12-18 Years		60.10%	R	Reportable
19-50 Years		49.58%	R	Reportable
51-64 Years		56.94%	R	Reportable
Total		58.40%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions				
Controlling High Blood Pressure (cbp)		50.85%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	71.33%	R	Reportable
Statin Therapy for Patients With Cardiovascular Disease (spc)	Y			
Received Statin Therapy: 21-75 Years (Male)		66.94%	R	Reportable
Statin Adherence 80%: 21-75 Years (Male)		63.07%	R	Reportable
Received Statin Therapy: 40-75 Years (Female)		63.82%	R	Reportable
Statin Adherence 80%: 40-75 Years (Female)		61.15%	R	Reportable
Received Statin Therapy: Total		65.68%	R	Reportable
Statin Adherence 80%: Total		62.31%	R	Reportable
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)				
Hemoglobin A1c (HbA1c) Testing		85.95%	R	Reportable
HbA1c Poor Control (>9.0%)		49.62%	R	Reportable
HbA1c Control (<8.0%)		42.29%	R	Reportable
HbA1c Control (<7.0%)		27.01%	R	Reportable
Eye Exam (Retinal) Performed		53.13%	R	Reportable
Medical Attention for Nephropathy		89.31%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		54.50%	R	Reportable
Statin Therapy for Patients With Diabetes (spd)	Y			
Received Statin Therapy		50.15%	R	Reportable
Statin Adherence 80%		60.65%	R	Reportable
Effectiveness of Care: Behavioral Health				
Antidepressant Medication Management (amm)	Y			
Effective Acute Phase Treatment		58.14%	R	Reportable
Effective Continuation Phase Treatment		39.31%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y			
Initiation Phase		29.04%	R	Reportable
Continuation and Maintenance (C&M) Phase		37.93%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y			
6-17 years - 30-Day Follow-Up		51.88%	R	Reportable
6-17 years - 7-Day Follow-Up		35.95%	R	Reportable
18-64 years - 30-Day Follow-Up		36.45%	R	Reportable
18-64 years - 7-Day Follow-Up		22.07%	R	Reportable
65+ years - 30-Day Follow-Up		31.11%	R	Reportable
65+ years - 7-Day Follow-Up		15.56%	R	Reportable
Total - 30-Day Follow-Up		40.22%	R	Reportable
Total - 7-Day Follow-Up		25.44%	R	Reportable
Follow-Up After Emergency Department Visit for Mental Illness (fum)	Y			
6-17 years - 30-Day Follow-Up		76.27%	R	Reportable
6-17 years - 7-Day Follow-Up		63.98%	R	Reportable
18-64 years - 30-Day Follow-Up		54.00%	R	Reportable
18-64 years - 7-Day Follow-Up		42.11%	R	Reportable
65+ years - 30-Day Follow-Up		60.53%	R	Reportable
65+ years - 7-Day Follow-Up		31.58%	R	Reportable
Total - 30-Day Follow-Up		61.01%	R	Reportable
Total - 7-Day Follow-Up		48.78%	R	Reportable
Follow-Up After High-Intensity Care for Substance Use Disorder (fui)	Y			
13-17 years - 30-Day Follow-Up		1.87%	R	Reportable
13-17 years - 7-Day Follow-Up		1.10%	R	Reportable
18-64 years - 30-Day Follow-Up		9.93%	R	Reportable
18-64 years - 7-Day Follow-Up		5.45%	R	Reportable
65+ years - 30-Day Follow-Up		1.04%	R	Reportable
65+ years - 7-Day Follow-Up		0.71%	R	Reportable
Total - 30-Day Follow-Up		8.39%	R	Reportable
Total - 7-Day Follow-Up		4.62%	R	Reportable
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fua)	Y			
30-Day Follow-Up: 13-17 Years		10.68%	R	Reportable
7-Day Follow-Up: 13-17 Years		5.13%	R	Reportable
30-Day Follow-Up: 18+ Years		18.87%	R	Reportable
7-Day Follow-Up: 18+ Years		12.01%	R	Reportable

30-Day Follow-Up: Total		18.53%	R	Reportable
7-Day Follow-Up: Total		11.72%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	79.51%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)		59.83%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)		81.82%	NA	Small Denominator
Pharmacotherapy for Opioid Use Disorder (pod)	Y			
16-64 years		19.57%	R	Reportable
65+ years		8.00%	NA	Small Denominator
Total		19.48%	R	Reportable
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	53.38%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
Blood glucose testing - 1-11 Years		48.16%	R	Reportable
Cholesterol Testing - 1-11 Years		30.43%	R	Reportable
Blood glucose and Cholesterol Testing - 1-11 Years		30.10%	R	Reportable
Blood glucose testing - 12-17 Years		66.81%	R	Reportable
Cholesterol Testing - 12-17 Years		42.02%	R	Reportable
Blood glucose and Cholesterol Testing - 12-17 Years		40.99%	R	Reportable
Blood glucose testing - Total		60.49%	R	Reportable
Cholesterol Testing - Total		38.10%	R	Reportable
Blood glucose and Cholesterol Testing - Total		37.30%	R	Reportable
Effectiveness of Care: Overuse/Appropriateness				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		0.66%	R	Reportable
Appropriate Treatment for Upper Respiratory Infection (uri)	Y			
3months-17 Years		88.30%	R	Reportable
18-64 Years		74.75%	R	Reportable
65+ Years		98.59%	R	Reportable
Total		85.08%	R	Reportable
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (aab)	Y			
3 months-17 Years		61.32%	R	Reportable
18-64 Years		39.32%	R	Reportable
65+ Years		96.98%	R	Reportable
Total		52.42%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		74.67%	R	Reportable
Use of Opioids at High Dosage (hdo)	Y	6.16%	R	Reportable
Use of Opioids From Multiple Providers (uop)	Y			
Multiple Prescribers		20.11%	R	Reportable
Multiple Pharmacies		5.59%	R	Reportable
Multiple Prescribers and Multiple Pharmacies		2.29%	R	Reportable
Risk of Continued Opioid Use (cou)	Y			
18-64 years - >=15 Days covered		6.13%	R	Reportable
18-64 years - >=31 Days covered		2.96%	R	Reportable
65+ years - >=15 Days covered		40.83%	R	Reportable
65+ years - >=31 Days covered		14.17%	R	Reportable
Total - >=15 Days covered		6.36%	R	Reportable
Total - >=31 Days covered		3.03%	R	Reportable
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
20-44 Years		73.88%	R	Reportable
45-64 Years		80.36%	R	Reportable
65+ Years		85.64%	R	Reportable
Total		76.92%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				
12-24 Months		90.61%	R	Reportable
25 Months - 6 Years		79.67%	R	Reportable
7-11 Years		84.22%	R	Reportable
12-19 Years		81.38%	R	Reportable
Annual Dental Visit (adv)	Y			
2-3 Years		58.81%	R	Reportable
4-6 Years		74.99%	R	Reportable
7-10 Years		78.40%	R	Reportable
11-14 Years		73.00%	R	Reportable

15-18 Years		63.24%	R	Reportable
19-20 Years		43.33%	R	Reportable
Total		69.01%	R	Reportable
Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)	Y			
Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years		28.70%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years		7.83%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years		61.11%	NA	Small Denominator
Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years		0.00%	NA	Small Denominator
Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years		44.76%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years		15.02%	R	Reportable
Total: Initiation of AOD Treatment: 13-17 Years		40.57%	R	Reportable
Total: Engagement of AOD Treatment: 13-17 Years		13.65%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years		38.94%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years		13.31%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years		59.49%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years		27.55%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years		40.60%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 18+ Years		11.49%	R	Reportable
Total: Initiation of AOD Treatment: 18+ Years		42.93%	R	Reportable
Total: Engagement of AOD Treatment: 18+ Years		15.45%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: Total		38.58%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: Total		13.11%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: Total		59.50%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: Total		27.37%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: Total		41.03%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: Total		11.85%	R	Reportable
Total: Initiation of AOD Treatment: Total		42.79%	R	Reportable
Total: Engagement of AOD Treatment: Total		15.35%	R	Reportable
Prenatal and Postpartum Care (ppc)				
Timeliness of Prenatal Care		90.51%	R	Reportable
Postpartum Care		75.43%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y			
1-11 Years		63.55%	R	Reportable
12-17 Years		61.36%	R	Reportable
Total		62.09%	R	Reportable
Utilization				
Well-Child Visits in the First 15 Months of Life (w15)				
0 Visits		4.14%	R	Reportable
1 Visit		2.43%	R	Reportable
2 Visits		4.38%	R	Reportable
3 Visits		4.38%	R	Reportable
4 Visits		4.38%	R	Reportable
5 Visits		13.63%	R	Reportable
6+ Visits		66.67%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)		55.72%	R	Reportable
Adolescent Well-Care Visits (awc)		34.21%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)			NR	Not Reported
Ambulatory Care: Disabled (ambc)			NR	Not Reported
Ambulatory Care: Other (ambd)			NR	Not Reported

Inpatient Utilization--General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)			NR	Not Reported
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y		NR	Not Reported
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y		NR	Not Reported
Identification of Alcohol and Other Drug Services: Other (iadd)	Y		NR	Not Reported
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y		NR	Not Reported
Mental Health Utilization: Disabled (mptc)	Y		NR	Not Reported
Mental Health Utilization: Other (mptd)	Y		NR	Not Reported
Antibiotic Utilization: Total (abxa)	Y		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y		NR	Not Reported
Antibiotic Utilization: Disabled (abxc)	Y		NR	Not Reported
Antibiotic Utilization: Other (abxd)	Y		NR	Not Reported
Risk Adjusted Utilization				
Plan All-Cause Readmissions (pcr)			R	Reportable
Health Plan Descriptive Information				
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NR	Not Reported
Enrollment by Product Line: Disabled (enpc)			NR	Not Reported
Enrollment by Product Line: Other (enpd)			NR	Not Reported
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			R	Reportable
Race/Ethnicity Diversity of Membership (rdm)			R	Reportable
Total Membership (tIm)			R	Reportable
Measures Collected using Electronic Clinical Data Systems				
Follow-Up Care for Children Prescribed ADHD Medication (add-e)	Y			
<i>Initiation Phase</i>			NR	Not Reported
<i>Continuation and Maintenance Phase</i>			NR	Not Reported
Breast Cancer Screening (bcs-e)			NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults (dsf)				
<i>Depression Screening: Total Total</i>			NR	Not Reported
<i>Follow-up on Positive Screen: Total Total</i>			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
<i>Utilization of PHQ-9 - Time period 1: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Time period 2: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Time period 3: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Total: Total Total</i>			NR	Not Reported
Depression Remission or Response for Adolescents and Adults (drr)				
<i>Follow-up PHQ-9: Total Total</i>			NR	Not Reported
<i>Depression Remission: Total Total</i>			NR	Not Reported
<i>Depression Response: Total Total</i>			NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)				
<i>Alcohol Use Screening: Total Total</i>			NR	Not Reported
<i>Counseling or Other Follow-up Positive Screen: Total Total</i>			NR	Not Reported
Adult Immunization Status (ais)				
<i>Influenza: Total</i>			NR	Not Reported
<i>Td or Tdap: Total</i>			NR	Not Reported
<i>Zoster: Total</i>			NR	Not Reported
<i>Composite: Total</i>			NR	Not Reported
Postpartum Depression Screening and Follow-Up (pds)				
<i>Depression Screening</i>			NR	Not Reported
<i>Follow-Up on Positive Screen</i>			NR	Not Reported
Prenatal Depression Screening and Follow-Up (pnd)				
<i>Depression Screening</i>			NR	Not Reported
<i>Follow-Up on Positive Screen</i>			NR	Not Reported
Prenatal Immunization Status (prs)				
<i>Influenza: Total</i>			NR	Not Reported

<i>Td or Tdap: Total</i>			NR	Not Reported
<i>Combination: Total</i>			NR	Not Reported